TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27424313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of n-3 FA 2 g + fenofibrate 160 mg
Study: 20855072
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg
Study: 27424313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of n-3 FA + fenofibrate
Study: 23428122
Drug: GABA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA treatment (25-30 mg/kg•d)
Study: 23428122
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for asthma
Study: 12670780
Drug: montelukast 10mg
Normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 10mg daily
Study: 12670780
Drug: budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide 400 microg twice a day (bid)
Study: 12670780
Drug: montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast 10 mg daily plus budesonide 400 microg bid
Study: 11910586
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group I)
Study: 11910586
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every 3 months (Group II)
Study: 11910586
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group III)
Study: 11910586
Drug: Acceptability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptability of the gel
Study: 1473437
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g 5‐ASA foam
Study: 1473437
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g 5‐ASA enema
Study: 6237836
Drug: Zimelidine (Z),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (Z), 200 mg by mouth, preceded by 1 hr and followed for 7 hr of oral ethanol (E) in juice dosed to maintain blood alcohol concentrations between 800 and 1000 mg/l
Study: 28138381
Drug: d-Cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d-Cycloserine (DCS) 50 mg administered 30 min prior to group social skills training
Study: 28138381
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 30 min prior to group social skills training
Study: 27703725
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly extended release exenatide for 24 weeks
Study: 24326981
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of vitamin E plus 400 mg of vitamin C
Study: 17727580
Drug: Standard gravitational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gravitational infusion sets without IV(2) flow
Study: 15685462
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (saline injection)
Study: 6282926
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IGIV), 5%, in 10% maltose, administered at a dose of 20 cc/kg
Study: 6282926
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IGIV), 5%, in 10% maltose, at doses lower than 20 cc/kg
Study: 6282926
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IGIV) administered at 20 cc/kg once every week (currently under evaluation)
Study: 6177709
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IGIV)
Study: 30666966
Drug: 2‐L low‐volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐L low‐volume bowel preparation regimen
Study: 30666966
Drug: 4‐L high‐volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐L high‐volume bowel preparation regimen
Study: 30666966
Drug: Low‐volume preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐volume preparation
Study: 21153945
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedative infusion (Group P, n=25)
Study: 15786484
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus family intervention
Study: 7797776
Drug: Insulin-glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glucose infusion followed by multidose subcutaneous insulin for > or = 3 months
Study: 23611569
Drug: Vilazodone 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 10, 20, 40, 60, and 80 mg/day
Study: 17660177
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 microg/kg combined with propofol 1 mg/kg
Study: 17660177
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 microg/kg combined with midazolam 0.05 mg/kg
Study: 11833836
Drug: Clinafloxacin 200
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin 200 mg IV every 12 hours
Study: 11833836
Drug: Piperacillin/tazobactam 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 3.375 g IV every 6 hours
Study: 10511931
Drug: AK incisions
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK incisions with collagen implants
Study: 10511931
Drug: AK incisions
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK incisions without collagen implants (Control)
Study: 7856671
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (10 L/min by face mask)
Study: 7856671
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy for ≤ 10 minutes
Study: 7856671
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy for > 10 minutes
Study: 20116706
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis
Study: 2686291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without antibiotic prophylaxis
Study: 7042092
Drug: IF radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF radiotherapy plus MOPP chemotherapy
Study: 30554882
Drug: BNO 1030
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNO 1030 (Imupret®) as a supplement to standard symptomatic therapy
Study: 26575144
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg bolus followed by 0.2 to 0.7 μg/kg/h infusion)
Study: 26575144
Drug: Propofol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (25 to 50 μg/kg/min infusion)
Study: 25123162
Drug: Multiple courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple courses of antenatal corticosteroids (ACS) therapy
Study: 25123162
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of antenatal corticosteroids (ACS) therapy
Study: 22757662
Drug: Sodium picosulphate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulphate (Picoprep) bowel preparation
Study: 19201016
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of desloratadine
Study: 19201016
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of desloratadine
Study: 12164403
Drug: Phlogenzym (bromelain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlogenzym (bromelain 90 mg, trypsin 48 mg, rutin 100 mg)
Study: 7812574
Drug: salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol (50 micrograms twice daily)
Study: 1972797
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms dexmedetomidine (MPV‐1440), a selective alpha 2‐adrenoceptor agonist
Study: 1972797
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atipamezole (MPV‐1248), a selective alpha 2‐adrenoceptor antagonist
Study: 31475470
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with non‐ablative fractional laser and intralesional steroid injection (1550‐nm erbium‐glass fractional laser treatment)
Study: 31475470
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with non‐ablative fractional laser and intralesional steroid injection
Study: 31475470
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroid injection alone)
Study: 27303788
Drug: S-1 (≥77.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (≥77.6 mg/m2/day)
Study: 27303788
Drug: S-1 (≤65.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (≤65.9 mg/m2/day)
Study: 27303788
Drug: GS (≥65.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS (≥65.1 mg/m2/day)
Study: 27303788
Drug: GS (≤53.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS (≤53.8 mg/m2/day)
Study: 23118932
Drug: GTP (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP (500 mg daily)
Study: 23118932
Drug: GTP (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP (500 mg daily) + TC (60-minute group exercise, 3 times/week)
Study: 21048953
Drug: Recombinant replication-defective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, at a dose of 10^10 or 10^11 adenovector particle units
Study: 21048953
Drug: Recombinant replication-defective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant replication-defective adenovirus type 5 (rAd5) vaccine
Study: 15969949
Drug: Rapidly disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly disintegrating stanol lecithin tablets (1.26 g stanols daily)
Study: 15969949
Drug: Slowly disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowly disintegrating capsules (1.01 g daily)
Study: 12324640
Drug: Polynutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polynutrient supplement (twice daily for 10 weeks)
Study: 12324640
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 10 weeks)
Study: 8643170
Drug: High-dose iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose iron therapy (100 mg at the end of HD treatment)
Study: 8643170
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron therapy (10, 20, or 40 mg per HD depending on haemoglobin, serum ferritin, and transferrin saturation)
Study: 8643170
Drug: Intravenous rHuEpo
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rHuEpo therapy
Study: 8643170
Drug: Subcutaneous rHuEpo
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEpo therapy
Study: 8643170
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of iron administration
Study: 8643170
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy in well-nourished patients (serum albumin > 40 g/l) without hyperparathyroidism
Study: 8643170
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy in patients with hyperparathyroidism
Study: 336178
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (control)
Study: 27406639
Drug: Antenatal integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal integrative medicine education programme plus standard care
Study: 22143925
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal saline (group A)
Study: 22143925
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of gadopentetate dimeglumine and normal saline (group B)
Study: 31777761
Drug: Asoprisnil 25
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 25 mg
Study: 14652471
Drug: Fear-avoidance-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fear-avoidance-based physical therapy (n = 34)
Study: 14652471
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care physical therapy (n = 32)
Study: 8866803
Drug: Five-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-valent pneumococcal conjugate vaccine (3 doses of 5 micrograms of types 6B, 14, 18, 19F, and 23F polysaccharides conjugated to CRM197)
Study: 8866803
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b vaccine (2 doses)
Study: 1632567
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 to 50 mg three times a day)
Study: 1632567
Drug: Nadolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (20 to 160 mg once a day)
Study: 6436700
Drug: Leuprolide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (1 mg subcutaneously daily)
Study: 6436700
Drug: Diethylstilbestrol (DES,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES, 3 mg by mouth daily)
Study: 20083693
Drug: pimecrolimus, 1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimecrolimus, 1%, cream
Study: 18274206
Drug: Combined levothyroxine
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined levothyroxine (50 microg) and liothyronine (12.5 microg) supplement
Study: 9539578
Drug: Interstitial thermometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial thermometry during hyperthermia treatment
Study: 31335198
Drug: Patient-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-led titration of insulin glargine 100 U/mL
Study: 31335198
Drug: Physician-led titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-led titration of insulin glargine 100 U/mL
Study: 28538261
Drug: Better Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Better Exercise Adherence after Treatment for Cancer (BEAT Cancer)
Study: 26541350
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (0.5 mg/kg intravenous methylprednisolone for 2 days followed by 12 mg daily oral methylprednisolone for 4 days)
Study: 26541350
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid therapy)
Study: 17109580
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Lactobacillus acidophilus and Bifidobacterium longum
Study: 10939775
Drug: Homeopathic or
Normalized name: Drainage Homeopathic Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic or conventional treatment according to patient preference
Study: 8622602
Drug: Acipimox (ACX)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (ACX) 500 mg (one dose)
Study: 8622602
Drug: One-dose ACX
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose ACX (500 mg)
Study: 1533478
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (Green Cross HB-vaccine)
Study: 1533478
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant vaccine (Engerix B)
Study: 1533478
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plasma-derived and yeast-derived vaccines
Study: 24402597
Drug: Patch
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch
Study: 28366818
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy (PDT) with scaling and root debridement
Study: 23767916
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of vitamin D3 per day (low dose)
Study: 23767916
Drug: 4,370 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,370 IU of vitamin D3 per day (high dose)
Study: 21204680
Drug: CAD+G (computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD+G (computer-assisted dieting plus self-management training)
Study: 19681255
Drug: 19% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19% sodium percarbonate brush-applied gel (Crest Night Effects)
Study: 19681255
Drug: Placebo brush-applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo brush-applied gel without peroxide
Study: 15186865
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of 241 insulin-treated patients
Study: 26308684
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil
Study: 26308684
Drug: Ambrisentan monotherapy
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan monotherapy (10 mg)
Study: 26308684
Drug: Tadalafil monotherapy
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil monotherapy (40 mg)
Study: 23038021
Drug: Powdered black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered black tea solids containing 429 mg of polyphenols
Study: 22045080
Drug: Low-dose adenosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adenosine (24 mg)
Study: 22045080
Drug: High-dose adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adenosine (36 mg)
Study: 15569335
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (2 g/day)
Study: 9306037
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of oral glucose
Study: 9306037
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of intravenous glucagon
Study: 9306037
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment for 10-14 days in 15 poorly controlled NIDDM patients
Study: 8371179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IA and BF/SM
Study: 24719474
Drug: Ad5HVR48.EnvA.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5HVR48.EnvA.01 vaccine (10^9 to 10^11 viral particles)
Study: 18754438
Drug: Ropivacaine 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.00 mg/kg (0.15%-0.20%)
Study: 18754438
Drug: Ropivacaine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.25 mg/kg (0.20%-0.25%)
Study: 18754438
Drug: Ropivacaine 1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1.50 mg/kg (0.30%-0.35%)
Study: 18754438
Drug: Ropivacaine 2.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2.00 mg/kg (0.30%-0.35%)
Study: 12592683
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western therapy (CWT)
Study: 10379638
Drug: Clozapine 12.5
Normalized name: clozapine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 12.5 mg alone
Study: 10379638
Drug: Clozapine 12.5
Normalized name: clozapine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 12.5 mg with erythromycin 1500 mg
Study: 1870835
Drug: Doxium (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxium (calcium dobesilate) 500 mg, 3 capsules daily for 6 months
Study: 1870835
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 capsules daily for 6 months
Study: 6362340
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin
Study: 31269891
Drug: Micronized palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized palmitoylethanolamide 600 mg/die
Study: 25827448
Drug: Terminalia arjuna
Normalized name: terminalia arjuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia arjuna (500 mg twice a day)
Study: 23063141
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (continued without modification)
Study: 21564523
Drug: Sotrastaurin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin (300 mg b.i.d.)
Study: 16849748
Drug: rIFL (reduced-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFL (reduced-dose bolus fluorouracil plus leucovorin and irinotecan)
Study: 12170038
Drug: Rescue dextropropoxyphene
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rescue dextropropoxyphene tablets
Study: 10446825
Drug: TNF-alpha (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha (1.25, 12.5, 125, or 250 pg/mL for 20 mins)